The page nobody gets to remove
Human phase 3a · REDEFINE 1 safety; June 22, 2025
What belongs beside a successful efficacy result?
Subject One finds a page folded behind the presentation board. He brings it to the front. There is no punch line this time. Doctide leaves space on the desk, and they read the record without rewriting what happened.
What changes here
Efficacy does not erase serious harms. [1]
Read the study details & dates
Same population, separate safety question
NCT05567796: phase 3a, adults without diabetes; weekly injected CagriSema versus its components and placebo. Safety populations: 2,106 CagriSema, 705 placebo. Serious events: 9.8% versus 6.1%; gastrointestinal events: 79.6% versus 39.9%; malignant neoplasms: 14 (0.7%) versus 4 (0.6%). [1]
What this does not establish
Cause-of-death adjudication is not treatment causality. Event-specific treatment attribution was not identified in the reviewed main paper.
Original sources
Sources reviewed November 3, 2026. Sponsor material is labeled; event dates are distinct from this editorial date. Trial identifiers identify the studies, not an invitation to enroll.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story